Search filters

List of works by Ian W. Flinn

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

scientific article published on 01 June 2000

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

scientific article published on 31 December 2013

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

scientific article

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.

scientific article

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma

scientific article published on 4 March 2006

A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia

scientific article

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

scientific article published on 17 December 2015

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma

scientific article

Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies

scientific article published on 14 August 2017

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

scientific article

Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma

scientific article published on 01 January 2001

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

scientific article published on 23 April 2013

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

scientific article published in April 2003

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

scientific article

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

scientific article published on 10 December 2017

Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.

scientific article published on 8 March 2004

B-Cell Receptor Pathobiology and Targeting in NHL ⬇️

scientific article published on October 1, 2012

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

scientific article published on 28 November 2017

CD37: the comeback kid ⬇️

scientific article published on October 13, 2011

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

scientific article published on 31 August 2017

Chronic lymphocytic leukemia

scientific article published on 01 January 1996

Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease

scientific article published on 12 December 2016

Chronic lymphocytic leukemia: advances in biology and therapeutics.

scientific article

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

scientific article published on 01 September 2006

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

scientific article

Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia

scientific article published on 04 October 2019

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

scientific article published on 8 June 2015

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.

scientific article

Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies.

scientific article published on April 2008

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

scientific article published on 5 February 2007

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

scientific article

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

scientific article published on 25 March 2015

Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma

scientific article published on 26 May 2015

Effects of chronic ethanol exposure on cardiac receptor-adenylyl cyclase coupling: studies in cultured embryonic chick myocytes and ethanol fed rats.

scientific article published on December 1991

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

scientific article

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

scientific article published on 15 December 2016

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

scientific article published on 6 June 2017

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

scientific article published on 10 January 2017

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia ⬇️

scientific article published on October 16, 2003

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

scientific article published on July 2005

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

scientific article

GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia ⬇️

scientific article published on March 1, 2013

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions

scientific article published on 01 April 2006

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas

scientific article

High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement

scientific article published on 01 February 2005

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

scientific article

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

scientific article

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

scientific article

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

scientific article

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

scientific article published on 01 January 2000

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

scientific article published on 3 August 2007

Leptomeningeal involvement in chronic lymphocytic leukemia

scientific article published on 01 July 1998

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

scientific article published on 07 January 2021

Lymphoma therapy: the challenges ahead

scientific article published on 01 September 2002

Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?

scientific article

Management of symptomatic, untreated chronic lymphocytic leukemia.

scientific article published on 13 November 2006

New approaches to blood and marrow transplantation for patients with low-grade lymphomas.

scientific article

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

scientific article published on 17 August 2011

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

scientific article

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

scientific article

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

scientific article

Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.

scientific article

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients

scientific article

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

scientific article published in January 2005

PI3K inhibitors and the search for the Holy Grail

scientific article published on 01 July 2018

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

scientific article

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

scientific article published on 01 August 2007

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

scientific article

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

scientific article published on 14 July 2014

Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia

scientific article published in December 2005

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

scientific article published on 12 June 2012

Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease

scientific article published on 01 August 2004

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

scientific article published on 7 February 2017

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

scientific article

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

scientific article

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

scientific article published on 21 May 2013

Ponatinib in refractory Philadelphia chromosome-positive leukemias

scientific article

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.

scientific article

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

scientific article published in September 2017

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

scientific article

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

scientific article

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

scientific article published on 15 March 2012

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.

scientific article

Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma

scientific article published on 28 February 2014

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

scientific article published on 27 April 2015

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma

scientific article

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

scientific article

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

scientific article

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

scientific article published on 2 February 2018

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

scientific article published on April 2007

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

scientific article (publication date: 4 July 2013)

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

scientific article published on 9 March 2015

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

scientific article published on 16 March 2020

The expanding options for front-line treatment in patients with newly diagnosed CML.

scientific article published on 08 April 2012

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

scientific article

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

scientific article

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

scientific article

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 10 February 2019

UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.

scientific article published in June 2001

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

scientific article published on 10 April 2017

Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.

scientific article published on September 2007

Using point-of-care CD34 enumeration to optimize PBSC collection conditions.

scientific article published in January 2001

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

scientific article published in August 2004

Paulina is supported by:

About Paulina

Help